ST6GALNAC2 Antibody

1. MicroRNAs miR-135b and miR-182 have the potential to reverse resistance to 5-fluorouracil (5-FU) in colorectal cancer (CRC) cells by targeting ST6GALNAC2 via the PI3K/AKT pathway. This discovery suggests potential chemotherapy targets for CRC treatment. PMID: 28767179
2. The miR-182/-135b/ST6GALNAC2/PI3K/AKT axis plays a role in regulating the progression of colorectal cancer. PMID: 29030743
3. Research indicates that mutations in B3GNT2, B4GALT2, and ST6GALNAC2 contribute to aberrant glycosylation and are involved in the pathogenesis of specific molecular subsets of colon and other gastrointestinal malignancies. PMID: 27004849
4. Studies have shown that ST6GalNAcII activates invasion in follicular thyroid cancer cells by regulating the PI3K/Akt pathway. PMID: 26820593
5. High expression levels of ST6GalNAcII are associated with the invasive phenotype of breast cancer. PMID: 24756995
6. ST6GalNAc II may participate in the glycosylation of Axl, and this glycosylation could mediate tumorigenicity, invasion, and distant metastasis of breast phyllodes tumor cells. PMID: 24961352
7. Research has identified the sialyltransferase ST6GalNAc2 as a novel suppressor of breast cancer metastasis. PMID: 24520024
8. Il-6 and Il-4 reduce galactosylation of the O-glycan substrate directly by decreasing the expression of the galactosyltransferase C1GalT1 and indirectly by increasing the expression of the sialyltransferase ST6GalNAc-II. PMID: 24398680
9. ST6GalNAc2 is a novel enzyme that regulates leukocyte adhesion under fluid shear. PMID: 23548905
10. The expression of the ST6-GalNAcII gene and activity of the CMP-NeuAc:GalNAc-IgA1 alpha2,6-sialyltransferase were higher in immunoglobulinA1-producing cell lines. PMID: 17418236
11. The ADG haplotype in the ST6GALNAC2 gene is a functional regulatory variant that may contribute to genetic susceptibility in a subset of patients where desialylation of IgA1 molecules is the primary causative pathogenesis of IgAN. PMID: 17480010
12. Reduced sialylation of serum IgA1 may result from decreased expression of ST6GALNAC2. PMID: 19170967
13. Potential genetic interactions of C1GALT1 and ST6GALNAC2 variants influence IgA1 O-glycosylation, disease predisposition, and disease severity. These interactions may contribute to the polygenic nature of IgA nephropathy. PMID: 19357720

Show More

Hide All

HGNC: 10867

OMIM: 610137

KEGG: hsa:10610

STRING: 9606.ENSP00000225276

UniGene: Hs.592105